Adolor scientists and clinicians, in close collaboration with experts in the field, have published the results of their work in world-renowned journals such as New England Journal of Medicine, Annals of Surgery, Journal of Pain, Pain, and Brain Research. Moreover, Adolor research has been presented at major society meetings such as the American College of Surgeons, American Society of Colon and Rectal Surgeons, American Society of Anesthesiologists, American Pain Society, and American Chemical Society.

Recent selected publications

Le Bourdonnec B, Windh R, Leister  L, Zhou QJ, Ajello CW, Gu M, Chu GH, Tuthill PA, Barker WM, Wiant DD, Graczyk, Belanger S, Cassel JA, Feschenko MS, Brogdon BL, Smith SA, Derelanko, MJ, Kutz S, Little PJ, DeHaven RN, DeHaven-Hudkins DL, Dolle RE. Spirocyclic Delta Opioid Receptor Agonists for the Treatment of Pain: Discovery of
N,N-Diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) benzamide (ADL5747). J Med Chem.  2009;52:5685-702.

Ludwig K, Enker WE, Delaney CP, Wolff BG, Du W, Fort JG, Cherubini M, Cucinotta J, Techner L. Gastrointestinal recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway. Arch Surg  2008;143(11):1098-1105.

DeHaven-Hudkins DL, DeHaven RN, Little PJ, Techner LM. The involvement of the mu-opioid receptor in gastrointestinal pathophysiology: therapeutic opportunities for antagonism at this receptor. Pharmacol Ther. 2008;117:162-187.

Le Bourdonnec B, Windh RT, Ajello CW, Leister LK, Gu M, Chu GH, Tuthill PA, Barker WM, Koblish M, Wiant DD, Graczyk TM, Belanger S, Cassel JA, Feschenko MS, Brogdon BL, Smith SA, Christ DD, Derelanko MJ, Kutz S, Little PJ, DeHaven RN, DeHaven-Hudkins DL, Dolle RE. Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859). J Med Chem. 2008; 9;51(19):5893-6.

Foss J, Fisher DM, Schmith VD. Pharmacokinetics of alvimopan and its metabolite in healthy volunteers and patients in postoperative ileus trials. Clin Pharm Therapeutics. 2008;83(5):770-776.

Senagore AJ, Bauer JJ, Du W, Techner L. Alvimopan accelerates gastrointestinal recovery after bowel resection regardless of age, sex, race, or concomitant medication use. Surgery. 2007;142(2):478-86.

Wolff BG, Weese JL, Ludwig KA, Delaney CP, Stamos MJ, Michelassi F, Du W, Techner L. Postoperative ileus-related morbidity profile in patients treated with alvimopan after bowel resection. J Am Coll Surg. 2007;204(4):609-16.

Delaney CP, Wolff BG; Viscusi ER, Senagore AJ, Fort JG, Du W, Techner L, Wallin, B. Alvimopan, for Postoperative Ileus Following Bowel Resection: a Pooled Analysis of Phase III Studies. Ann Surg. 2007;245(3):355-363. Comment in: Ann Surg 2007 245(3):364-5.

If you have any questions, please contact Adolor Corporation Medical Information at 1-866-4ADOLOR (1-866-423-6567).